Aishwarya Dash: Simplifying Bone Marrow Mesenchymal Stromal Cell Isolation
Aishwarya Dash, PHD Scholar at Postgraduate Institute of Medical Education and Research, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Indian Journal of Hematology and Blood Transfusion, adding:
“Publication Announcement!
Happy to share that our paper, ‘A Rapid and Cost-Effective Erythrocyte Lysis Based Method for Isolation and Characterization of Human Bone Marrow Mesenchymal Stromal Cells,’ has been published in the Indian Journal of Hematology and Blood Transfusion.
Our study presents a simple, rapid, and cost-effective approach to isolate and culture human bone marrow mesenchymal stromal cells (BM-MSCs), offering a practical method for research laboratories.
Grateful to my supervisors, mentors, and colleagues for their valuable support and guidance throughout this work.”
Title: A Rapid and Cost-Effective Erythrocyte Lysis Based Method for Isolation and Characterization of Human Bone Marrow Mesenchymal Stromal Cells
Authors: Aishwarya Dash, Man Updesh Singh Sachdeva, Nabhajit Mallik, Sreejesh Sreedharanunni, Manni Luthra-Guptasarma, Pankaj Malhotra
Stay updated with Hemostasis Today.
-
Oct 18, 2026, 15:21Eleonora Gambineri: First Results of the IEI-Haem Consortium at ESID 2026
-
Oct 18, 2026, 15:17Alexey Kulikov: Could Platelets Reveal Frailty Before Physical Signs Appear?
-
Oct 18, 2026, 15:06Elisa Rossi: Advancing HHT Research at the 16th International Conference
-
Oct 18, 2026, 14:54Caitlin Raymond: Could the Apheresis Circuit Itself Modulate Immunity?
-
Oct 18, 2026, 13:0810 Posts Not to Miss This Week
-
Oct 18, 2026, 12:58Pierpaolo Di Micco: DOACs vs Vitamin K Antagonists in Long-Term Anticoagulation
-
Oct 18, 2026, 12:51Arianne Missimer: Understanding Ferritin Levels Beyond the Normal Range
-
Oct 18, 2026, 12:37Roberto C. Iglesias: Colon Cancer Prevention Beyond Supplements and Vitamins
-
Oct 18, 2026, 12:27Rafael Alejandro Camero Del Vecchio: Paroxysmal Nocturnal Hemoglobinuria Advancing Complement Inhibition with Ravulizumab